NEW YORK (GenomeWeb) – DiaCarta and MIODx today said they plan to codevelop a diagnostic test to predict immunotherapy response based on MIODx's immune sequencing technology, ClonoMap.
The test will be developed and validated at DiaCarta's CLIA-certified laboratories in the San Francisco Bay Area and Nanjing, China. MIODx is an early-stage immunogenomics company based in San Jose, California, developing a T-cell receptor and B-cell receptor sequencing platform.
Financial and other terms of the deal were not disclosed.